222 publications
Elosulfase alfa (Vimizim®) for the treatment of Morquio A syndrome
Zorginstituut Nederland carried out a reassessment of the medicinal product elosulfase alfa (Vimizim®).
Ibrutinib (Imbruvica®) for the treatment of chronic lymphatic leukaemia
Zorginstituut Nederland carried out an assessment of the medicinal product ibrutinib (Imbruvica®), for the first-line treatment ...
Cysteamine with delayed release (Procysbi®)
Zorginstituut Nederland carried out an assessment of the medicine cysteamine with delayed release (Procysbi®) whereby they ...
A paradigm shift in perception, learning and action - summary of the second advice of the Committee Innovation Health Care Professions & Education
Summary of the second report of The Committee Innovation Health Care Professions & Education.
Daclizumab (Zinbryta®) for the treatment of relapsing (recidive) forms of multiple sclerosis (RMS)
Zorginstituut Nederland carried out a marginal assessment of the medicine daclizumab (Zinbryta ® ), whereby they came to the ...
Palbociclib (Ibrance®) for the treatment of metastatic breast cancer
Zorginstituut Nederland carried out an assessment of the medicine palbociclib (Ibrance®), whereby they came to the following ...
Netupitant - palonosetron (Akynzo®) for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy
Zorginstituut Nederland has assessed the medicine netupitant/palonosetron (Akynzeo®), whereby they came to the following ...
Fingolimod (Gilenya®)
Zorginstituut Nederland has advised on amending the conditional inclusion of the medicine fingolimod (Gilenya®) in the Medicines ...
Future scenarios about drug development and drug pricing
This report is the result of a consultative and deliberative process — initiated by the Belgian Healthcare Knowledge Centre (KCE) ...
Guideline for economic evaluations in healthcare
This new Guideline unifies all previously available Dutch guidelines, links up with international developments, provides un ...